JANX Stock Price, Janux Therapeutics, Inc. Quote, Chart

Market Summary

USD47.17-0.34

Delayed

-0.72%

JANX Stock Price

View Fullscreen

JANX RSI Chart

JANX Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-43.99

Price/Sales (Trailing)

167.58

Price/Free Cashflow

-45.92

JANX Price/Sales (Trailing)

JANX Profitability

Return on Equity

-8.48%

Return on Assets

-8.07%

Free Cashflow Yield

-2.18%

JANX Fundamentals

JANX Revenue

Revenue (TTM)

14.6M

Rev. Growth (Yr)

-55.63%

Rev. Growth (Qtr)

-83.49%

JANX Earnings

Earnings (TTM)

-55.6M

Earnings Growth (Yr)

15.46%

Earnings Growth (Qtr)

-25.53%

Breaking Down JANX Revenue

Last 7 days

-3.6%

Last 30 days

-1.6%

Last 90 days

400.2%

Trailing 12 Months

274.4%

How does JANX drawdown profile look like?

JANX Financial Health

Current Ratio

62.09

JANX Investor Care

Shares Dilution (1Y)

23.95%

Diluted EPS (TTM)

-1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.6M	0	0	0
2023	6.7M	9.6M	10.3M	16.2M
2022	3.4M	3.3M	3.9M	4.0M
2021	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Janux Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-438,722	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	31,456	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-31,456	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	1,700	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-1,700	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-84,985	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-447,949	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	11,388	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-11,388	-
Feb 29, 2024	gujrathi sheila	acquired	-	-	2,986	-

Which funds bought or sold JANX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.4	427,832	612,302	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	757,970	757,970	-%
May 15, 2024	Tudor Investment Corp Et Al	new	-	241,525	241,525	-%
May 15, 2024	BARCLAYS PLC	reduced	-67.52	73,000	584,000	-%
May 15, 2024	Driehaus Capital Management LLC	new	-	7,193,220	7,193,220	0.07%
May 15, 2024	Scientech Research LLC	new	-	533,651	533,651	0.28%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-46.25	416,333	886,319	-%
May 15, 2024	MORGAN STANLEY	added	79.74	3,840,630	4,564,350	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	new	-	327,367	327,367	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	739,000	739,000	-%

Are Funds Buying or Selling JANX?

Are funds buying JANX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JANX

No. of Funds

Unveiling Janux Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	ra capital management, l.p.	19.99%	10,593,395	SC 13D/A
Mar 04, 2024	avalon ventures xi, l.p.	7.7%	3,948,495	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	5.3%	2,427,414	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.8%	6	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	campbell david alan	5.3%	2,545,075	SC 13G/A
Feb 01, 2024	bregua corp	8.3%	3,830,257	SC 13G/A
Nov 16, 2023	avalon ventures xi, l.p.	9.5%	4,387,217	SC 13D/A
Jul 10, 2023	citadel advisors llc	4.9%	6	SC 13G

Recent SEC filings of Janux Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	S-3ASR	S-3ASR
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Mar 08, 2024	10-K	Annual Report
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Janux Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Janux Therapeutics, Inc. News

Latest updates

Janux Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-83.5%	1,252	7,586	2,517	3,240	2,822	1,714	1,813	373	132	1,616	1,159	482	380
Operating Expenses	15.1%	21,413	18,598	18,330	21,805	22,329	21,111	19,835	19,626	15,131	15,106	12,062	6,734	2,664
S&GA Expenses	-100.0%	-	6,357	6,438	6,881	6,464	5,677	6,098	5,540	4,947	3,937	3,656	1,997	739
R&D Expenses	14.9%	14,070	12,241	11,892	14,924	15,865	15,434	13,737	14,086	10,184	11,169	8,406	4,737	1,925
Net Income	-25.5%	-14,760	-11,758	-11,568	-17,508	-17,459	-16,065	-16,696	-16,888	-13,410	-13,416	-10,766	-6,206	-2,284
Net Income Margin	-5.6%	-3.81*	-3.61*	-6.08*	-7.06*	-9.98*	-15.64*	-15.36*	-16.61*	-12.92*	-8.98*	-	-	-
Free Cashflow	-44.3%	-15,034	-10,416	-12,179	-15,634	-14,196	-13,969	-15,934	-6,971	-12,493	-11,654	-5,931	-6,283	5,410

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	81.1%	689	380	387	342	353	364	376	385	369	380	391	397	-
Current Assets	88.6%	659	349	355	309	321	332	344	358	365	377	390	397	16.00
Cash Equivalents	1008.1%	213	19.00	17.00	34.00	30.00	51.00	65.00	58.00	55.00	36.00	39.00	252	8.00
Net PPE	-6.9%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	4.00	3.00	1.00	1.00	0.00	0.00
Liabilities	-7.9%	33.00	36.00	38.00	42.00	42.00	43.00	44.00	42.00	13.00	13.00	14.00	12.00	9.00
Current Liabilities	-18.6%	11.00	13.00	14.00	18.00	16.00	17.00	16.00	13.00	13.00	13.00	12.00	9.00	3.00
Shareholder's Equity	90.4%	656	344	349	299	311	321	332	344	356	366	377	385	-
Retained Earnings	-8.7%	-183	-168	-157	-145	-127	-110	-94.40	-77.71	-60.82	-47.41	-34.00	-23.23	-14.74
Additional Paid-In Capital	63.9%	840	512	507	446	440	433	428	423	418	414	411	408	0.00
Shares Outstanding	12.1%	52.00	46.00	46.00	42.00	42.00	42.00	41.00	41.00	41.00	41.00	18.00	10.00	-
Float	-	-	-	-	280	-	-	-	205	-	-	-	526	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-49.9%	-14,837	-9,901	-11,709	-15,054	-13,911	-11,913	-13,414	-6,073	-11,522	-10,481	-5,854	-6,204	5,563	-	-	-
Share Based Compensation	25.5%	5,625	4,483	4,548	5,501	5,473	4,205	4,596	4,444	3,958	2,944	2,566	1,277	123	-	28.00	2.00
Cashflow From Investing	-1122.5%	-113,736	11,123	-61,451	17,874	-8,740	-1,604	19,763	9,039	31,068	7,326	-205,539	-142,597	-153	-	-	-
Cashflow From Financing	38669.1%	322,171	831	56,609	528	1,580	191	-	308	1.00	164	-843	329,657	57,546	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JANX Income Statement

2024-03-31

Unaudited Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 1,252	$ 2,048
Operating expenses:
Research and development	14,070	15,865
General and administrative	7,343	6,464
Total operating expenses	21,413	22,329
Loss from operations	(20,161)	(20,281)
Other income:
Interest income	5,401	2,822
Total other income	5,401	2,822
Net loss	(14,760)	(17,459)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net	(1,189)	796
Comprehensive loss	$ (15,949)	$ (16,663)
Net loss per common share, basic	$ (0.3)	$ (0.42)
Net loss per common share, diluted	$ (0.3)	$ (0.42)
Weighted-average shares of common stock outstanding, basic	49,049,741	41,763,971
Weighted-average shares of common stock outstanding diluted	49,049,741	41,763,971

JANX Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 212,803	$ 19,205
Accounts receivable	519	0
Short-term investments	438,960	324,823
Prepaid expenses and other current assets	6,384	5,213
Total current assets	658,666	349,241
Restricted cash	816	816
Property and equipment, net	6,517	7,003
Operating lease right-of-use assets	20,461	20,838
Other long-term assets	2,524	2,509
Total assets	688,984	380,407
Current liabilities:
Accounts payable	2,254	2,424
Accrued expenses	5,810	7,387
Current portion of deferred revenue	972	1,705
Current portion of operating lease liabilities	1,573	1,517
Total current liabilities	10,609	13,033
Operating lease liabilities, net of current portion	22,612	23,025
Total liabilities	33,221	36,058
Commitments and contingencies (Note 3)
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; authorized shares -10,000,000 at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; authorized shares - 200,000,000 at March 31, 2024 and December 31, 2023, respectively; issued shares - 51,846,342 and 46,262,759 at March 31, 2024 and December 31, 2023, respectively; outstanding shares - 51,840,571 and 46,252,440 at March 31, 2024 and December 31, 2023, respectively	51	46
Additional paid-in capital	839,759	512,401
Accumulated other comprehensive income (loss)	(524)	665
Accumulated deficit	(183,523)	(168,763)
Total stockholders' equity	655,763	344,349
Total liabilities and stockholders' equity	$ 688,984	$ 380,407

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

CEO	Dr. David Alan Campbell Ph.D.
WEBSITE	januxrx.com
INDUSTRY	Biotechnology
EMPLOYEES	67

Janux Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Janux Therapeutics, Inc.? What does JANX stand for in stocks?

JANX is the stock ticker symbol of Janux Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Janux Therapeutics, Inc. (JANX)?

As of Fri May 17 2024, market cap of Janux Therapeutics, Inc. is 2.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers. The fair value of Janux Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Janux Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JANX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Janux Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JANX is over valued or under valued. Whether Janux Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Janux Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JANX.

What is Janux Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, JANX's PE ratio (Price to Earnings) is -43.99 and Price to Sales (PS) ratio is 167.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JANX PE ratio will change depending on the future growth rate expectations of investors.